123
IMMEDIATE RELEASE
MONTREAL, March 22, 2018 – ExCellThera Inc. announced today the appointment of David Millette as Chief Financial and Legal Officer effective April 3, 2018.
Mr. Millette combines a solid background in finance and law, having practised in the areas of accounting, finance and management consulting with a leading firm of chartered professional accountants for several years, and in the areas of corporate and securities law, financings and business acquisitions and sales for over a decade, including several years as a partner, with a top tier international law firm. He has a broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare. Mr. Millette is a lawyer, holds a bachelor of commerce and a law degree from the University of Montreal, and holds the designations of Chartered Professional Accountant (CPA, CA) and Chartered Financial Analyst (CFA).
“We are pleased to welcome David to the ExCellThera team,” said Dr. Guy Sauvageau, President and Chief Executive Officer. “He brings with him extensive financial, legal and strategic experience, and we anticipate to his contributions as we continue to execute our strategy. We expect to draw on his broad range of experience and competencies as ExCellThera continues its trajectory as a growing biotech company.”
– 30 –
For further information:
Dr. Guy Sauvageau
President and Chief Executive Officer
guy.sauvageau@excellthera.ca
David Millette
Chief Financial and Legal Officer
david.millette@excellthera.ca
Media Relations:
Lisa Willemse
ExCellThera
lisa.willemse@excellthera.ca
613-304-2108
RELATED LINKS:
http://www.excellthera.ca
About ExCellThera Inc.
ExCellThera is a biotechnology company focused on developing robust and cost-effective ways of growing blood stem cells for therapeutic use. ExCellThera’s lead solution, ECT-001, ExCellThera is currently completing a 25-patient Phase I/II clinical trial for blood malignancies and beginning a 20-patient Phase I/II clinical trial for multiple myeloma. The company launched in June 2015 and is developing a range of products, including gene therapy applications, as well as supporting early phase clinical trials. Visit www.excellthera.ca for more information.